Product Code: GVR-3-68038-694-3
Breast Cancer Diagnostics Market Growth & Trends:
The global breast cancer diagnostics market size is expected to reach USD 7.7 billion by 2030, according to a new study by Grand View Research, Inc.. The market is expected to expand at a CAGR of 7.4% from 2023 to 2030. The growth is largely attributable to the increasing geriatric population exposed to the risk of breast cancer and early detection coupled with increasing awareness about breast cancer.
The introduction of 3D mammography or digital breast tomosynthesis, which is more accurate than 2D mammography, supports market growth. This advanced technology can detect 40.0% more cancers than 2D mammograms and reduce patient recalls. Rapid technological advancements are a major factor expected to drive the market over the coming years.
Companies are adopting strategies that allow them to use their resources to aid in the development of new products, as well as enhance their supply chain. In November 2019, Exact Sciences Corporation announced the acquisition of Genomic Health, which was expected to help enhance the company's market position and offerings by acquiring its product portfolio. In January 2021, Hologic Inc. announced that it has agreed to acquire Biotheranostics for approximately US$ 230 million. Biotheranostics is a commercial-stage molecular diagnostics provider for breast and metastatic cancers.
The increasing launch of predictive and companion diagnostic tests for breast cancer is expected to boost the market growth. Recent launches in the segment include BRACAnalysis CDx by Myriad Genetics, which received FDA approval in 2018 as breast cancer companion diagnostics. In May 2019, QIAGEN introduced therascreen PIK3CA RGQ PCR Kit as a companion diagnostic for Novartis proprietary PIQRAY in guiding treatment decisions from tissue and liquid biopsy.
In January 2019, the Fujifilm Holdings Corporation introduced its Tomosynthesis Biopsy option for ASPIRE Cristalle mammography system. This technique was expected to enable physicians to detect breast cancers more efficiently compared to others by providing an enhanced 3D image and a digital mammogram.
However, there are specific risk factors associated with these imaging procedures. They involve administering high doses of fluorescent and barium contrast agents, as well as radiation exposure in the case of imaging and endoscopic procedures, which can cause several adverse effects such as nausea or diarrhea. The risks of ionizing radiation exposure associated with the use of CT, MRI, and X-rays, as well as the use of radioactive tracer injections in PET can limit the adoption of such screening procedures. Therefore, factors such as adverse effects of imaging act as a challenge for the companies in this market.
Breast Cancer Diagnostics Market Report Highlights:
- The imaging segment held the largest revenue share in 2022 and the blood tests segment is expected to grow at the fastest rate
- By product, the instrument-based products segment accounted for the largest revenue share in 2022 due to government initiatives such as mandatory screening in developed countries such as the U.S., Canada, and the U.K. for women above 45 years of age, increasing the overall testing and screening of breast cancer
- The platform-based products segment is expected to witness the fastest growth over the forecast period. These tests are mostly used for assessing the efficacy of chemotherapy and targeted therapy in women
- By application, the diagnostic and predictive segment dominated the market in 2022 and the prognostic segment is expected to witness the fastest CAGR over the forecast period due to increasing collaborations and efforts for advancements in diagnostics
- The hospitals and clinics segment dominated the market in 2022
- The medical labs and diagnostics centers segment is expected to witness the fastest CAGR over the forecast period due to an increase in platform-based testing such as NGS, and PCR
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Type
- 1.1.2. Product
- 1.1.3. Application
- 1.1.4. End-use
- 1.1.5. Regional scope
- 1.1.6. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. Product outlook
- 2.2.3. Application outlook
- 2.2.4. End-use outlook
- 2.2.5. Regional outlook
- 2.3. Competitive Insights
Chapter 3. Breast Cancer Diagnostics Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Penetration & Growth Prospect Mapping
- 3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
- 3.4. Breast Cancer Diagnostics Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
- 3.4.1.1. Supplier power
- 3.4.1.2. Buyer power
- 3.4.1.3. Substitution threat
- 3.4.1.4. Threat of new entrant
- 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
- 3.4.2.1. Political landscape
- 3.4.2.2. Technological landscape
- 3.4.2.3. Economic landscape
Chapter 4. Breast Cancer Diagnostics: Type Estimates & Trend Analysis
- 4.1. Breast Cancer Diagnostics Market, Key Takeaways
- 4.2. Breast Cancer Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
- 4.3. Imaging
- 4.3.1. Imaging market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.4. Biopsy
- 4.4.1. Biopsy market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.5. Genomic Tests
- 4.5.1. Genomic tests market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.6. Blood Tests
- 4.6.1. Blood tests market estimates and forecasts, 2018 to 2030 (USD Million)
- 4.7. Others
- 4.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 5. Breast Cancer Diagnostics: Product Estimates & Trend Analysis
- 5.1. Breast Cancer Diagnostics Market, Key Takeaways
- 5.2. Breast Cancer Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
- 5.3. Platform-based Products
- 5.3.1. Platform-based products market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.3.1.1. Next-generation sequencing
- 5.3.1.1.1. Next-generation sequencing market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.3.1.2. Microarrays
- 5.3.1.2.1. Microarrays market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.3.1.3. PCR
- 5.3.1.3.1. PCR market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.3.1.4. Others
- 5.3.1.4.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4. Instruments-based Products
- 5.4.1. Instruments-based products market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.1.1. Imaging
- 5.4.1.1.1. Imaging market estimates and forecasts, 2018 to 2030 (USD Million)
- 5.4.1.2. Biopsy
- 5.4.1.2.1. Biopsy market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 6. Breast Cancer Diagnostics: Application Estimates & Trend Analysis
- 6.1. Breast Cancer Diagnostics Market, Key Takeaways
- 6.2. Breast Cancer Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
- 6.3. Screening
- 6.3.1. Screening market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.4. Diagnostic and Predictive
- 6.4.1. Diagnostic and predictive market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.5. Prognostic
- 6.5.1. Prognostic market estimates and forecasts, 2018 to 2030 (USD Million)
- 6.6. Research
- 6.6.1. Research market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 7. Breast Cancer Diagnostics: End-use Estimates & Trend Analysis
- 7.1. Breast Cancer Diagnostics Market, Key Takeaways
- 7.2. Breast Cancer Diagnostics Market: Movement & Market Share Analysis, 2022 & 2030
- 7.3. Hospitals & Clinics
- 7.3.1. Hospitals & clinics market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.4. Diagnostic Centers and Medical Laboratories
- 7.4.1. Diagnostic centers and medical laboratories market estimates and forecasts, 2018 to 2030 (USD Million)
- 7.5. Others
- 7.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
Chapter 8. Breast Cancer Diagnostics Market: Regional Estimates & Trend Analysis
- 8.1. Regional Outlook
- 8.2. Breast Cancer Diagnostics Market by Region: Key Takeaway
- 8.3. North America
- 8.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.3.2. U.S.
- 8.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.3.3. Canada
- 8.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4. Europe
- 8.4.1. UK
- 8.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.2. Germany
- 8.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.3. France
- 8.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.4. Italy
- 8.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.5. Spain
- 8.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.6. Sweden
- 8.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.7. Norway
- 8.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.4.8. Denmark
- 8.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5. Asia Pacific
- 8.5.1. Japan
- 8.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5.2. China
- 8.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5.3. India
- 8.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5.4. Australia
- 8.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5.5. Thailand
- 8.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.5.6. South Korea
- 8.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.6. Latin America
- 8.6.1. Brazil
- 8.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.6.2. Mexico
- 8.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.6.3. Argentina
- 8.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.7. MEA
- 8.7.1. Saudi Arabia
- 8.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.7.2. South Africa
- 8.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.7.3. UAE
- 8.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
- 8.7.4. Kuwait
- 8.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis, By Key Market Participants
- 9.2. Company/Competition Categorization
- 9.2.1. Hologic Inc.
- 9.2.1.1. Company overview
- 9.2.1.2. Financial performance
- 9.2.1.3. Product Benchmarking
- 9.2.1.4. Strategic initiatives
- 9.2.2. Genomic Health (Exact Sciences Corporation)
- 9.2.2.1. Company overview
- 9.2.2.2. Financial performance
- 9.2.2.3. Product benchmarking
- 9.2.2.4. Strategic initiatives
- 9.2.3. BD
- 9.2.3.1. Company overview
- 9.2.3.2. Financial performance
- 9.2.3.3. Product benchmarking
- 9.2.3.4. Strategic initiatives
- 9.2.4. Danaher
- 9.2.4.1. Company overview
- 9.2.4.2. Financial performance
- 9.2.4.3. Product benchmarking
- 9.2.4.4. Strategic initiatives
- 9.2.5. Koninklijke Philips N.V.
- 9.2.5.1. Company overview
- 9.2.5.2. Financial performance
- 9.2.5.3. Product benchmarking
- 9.2.5.4. Strategic initiatives
- 9.2.6. QIAGEN
- 9.2.6.1. Company overview
- 9.2.6.2. Financial performance
- 9.2.6.3. Product benchmarking
- 9.2.6.4. Strategic initiatives
- 9.2.7. Thermo Fisher Scientific Inc.
- 9.2.7.1. Company overview
- 9.2.7.2. Financial performance
- 9.2.7.3. Product benchmarking
- 9.2.7.4. Strategic initiatives
- 9.2.8. Myriad Genetics, Inc.
- 9.2.8.1. Company overview
- 9.2.8.2. Financial performance
- 9.2.8.3. Product benchmarking
- 9.2.8.4. Strategic initiatives
- 9.2.9. Argon Medical Devices, Inc.
- 9.2.9.1. Company overview
- 9.2.9.2. Financial performance
- 9.2.9.3. Product benchmarking
- 9.2.9.4. Strategic initiatives
- 9.2.10. F. Hoffmann-La Roche Ltd.
- 9.2.10.1. Company overview
- 9.2.10.2. Financial performance
- 9.2.10.3. Product benchmarking
- 9.2.10.4. Strategic initiatives